Tarsus Pharmaceuticals (TARS) Competitors $47.30 +2.81 (+6.32%) (As of 11/1/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends TARS vs. FUSN, PRVL, HARP, CBMG, MGTX, ELAN, CYTK, NUVL, BPMC, and KRYSShould you be buying Tarsus Pharmaceuticals stock or one of its competitors? The main competitors of Tarsus Pharmaceuticals include Fusion Pharmaceuticals (FUSN), Prevail Therapeutics (PRVL), Harpoon Therapeutics (HARP), Cellular Biomedicine Group (CBMG), MeiraGTx (MGTX), Elanco Animal Health (ELAN), Cytokinetics (CYTK), Nuvalent (NUVL), Blueprint Medicines (BPMC), and Krystal Biotech (KRYS). These companies are all part of the "medical" sector. Tarsus Pharmaceuticals vs. Fusion Pharmaceuticals Prevail Therapeutics Harpoon Therapeutics Cellular Biomedicine Group MeiraGTx Elanco Animal Health Cytokinetics Nuvalent Blueprint Medicines Krystal Biotech Tarsus Pharmaceuticals (NASDAQ:TARS) and Fusion Pharmaceuticals (NASDAQ:FUSN) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, earnings, community ranking, media sentiment, analyst recommendations, risk, dividends, institutional ownership and profitability. Does the MarketBeat Community prefer TARS or FUSN? Tarsus Pharmaceuticals received 3 more outperform votes than Fusion Pharmaceuticals when rated by MarketBeat users. Likewise, 65.67% of users gave Tarsus Pharmaceuticals an outperform vote while only 64.06% of users gave Fusion Pharmaceuticals an outperform vote. CompanyUnderperformOutperformTarsus PharmaceuticalsOutperform Votes4465.67% Underperform Votes2334.33% Fusion PharmaceuticalsOutperform Votes4164.06% Underperform Votes2335.94% Which has more volatility and risk, TARS or FUSN? Tarsus Pharmaceuticals has a beta of 1.07, suggesting that its share price is 7% more volatile than the S&P 500. Comparatively, Fusion Pharmaceuticals has a beta of -0.69, suggesting that its share price is 169% less volatile than the S&P 500. Do analysts prefer TARS or FUSN? Tarsus Pharmaceuticals presently has a consensus target price of $51.60, suggesting a potential upside of 9.09%. Fusion Pharmaceuticals has a consensus target price of $20.25, suggesting a potential downside of 6.03%. Given Tarsus Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts plainly believe Tarsus Pharmaceuticals is more favorable than Fusion Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tarsus Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.00Fusion Pharmaceuticals 0 Sell rating(s) 13 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.07 Does the media refer more to TARS or FUSN? In the previous week, Tarsus Pharmaceuticals had 7 more articles in the media than Fusion Pharmaceuticals. MarketBeat recorded 7 mentions for Tarsus Pharmaceuticals and 0 mentions for Fusion Pharmaceuticals. Tarsus Pharmaceuticals' average media sentiment score of 0.61 beat Fusion Pharmaceuticals' score of 0.00 indicating that Tarsus Pharmaceuticals is being referred to more favorably in the media. Company Overall Sentiment Tarsus Pharmaceuticals Positive Fusion Pharmaceuticals Neutral Which has better earnings and valuation, TARS or FUSN? Fusion Pharmaceuticals has lower revenue, but higher earnings than Tarsus Pharmaceuticals. Fusion Pharmaceuticals is trading at a lower price-to-earnings ratio than Tarsus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTarsus Pharmaceuticals$17.45M103.11-$135.89M-$4.48-10.56Fusion Pharmaceuticals$2.07M885.53-$94.90M-$1.42-15.18 Do institutionals and insiders believe in TARS or FUSN? 90.0% of Tarsus Pharmaceuticals shares are owned by institutional investors. Comparatively, 72.9% of Fusion Pharmaceuticals shares are owned by institutional investors. 8.3% of Tarsus Pharmaceuticals shares are owned by insiders. Comparatively, 7.8% of Fusion Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Is TARS or FUSN more profitable? Tarsus Pharmaceuticals has a net margin of -180.00% compared to Fusion Pharmaceuticals' net margin of -4,136.55%. Fusion Pharmaceuticals' return on equity of -48.74% beat Tarsus Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Tarsus Pharmaceuticals-180.00% -63.99% -47.64% Fusion Pharmaceuticals -4,136.55%-48.74%-36.87% SummaryTarsus Pharmaceuticals beats Fusion Pharmaceuticals on 14 of the 19 factors compared between the two stocks. Ad Timothy SykesCountdown to the biggest trade of my 25 yr careerTim Sykes - the world’s most apolitical Millionaire trader - just sat down for an urgent election interview… Breaking down the ONE MOVE you must make before the November 5th election to set yourself up for a prosperous 2025.Click here to see the surprising reason why Get Tarsus Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for TARS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TARS vs. The Competition Export to ExcelMetricTarsus PharmaceuticalsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.80B$3.15B$5.32B$8.52BDividend YieldN/A1.77%5.07%4.13%P/E Ratio-10.5615.47127.5316.08Price / Sales103.11321.091,490.6892.20Price / CashN/A149.0539.5134.18Price / Book7.954.024.765.07Net Income-$135.89M-$42.25M$118.77M$225.46M7 Day Performance20.02%1.81%-0.38%0.06%1 Month Performance46.48%8.56%6.06%3.93%1 Year Performance225.98%35.10%38.14%32.50% Tarsus Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TARSTarsus Pharmaceuticals0.7604 of 5 stars$47.30+6.3%$51.60+9.1%+226.0%$1.69B$17.45M-10.5650Positive NewsFUSNFusion PharmaceuticalsN/A$21.55flat$20.25-6.0%N/A$1.83B$2.07M-15.18101PRVLPrevail TherapeuticsN/A$23.00flatN/AN/A$787.66MN/A-10.0066HARPHarpoon Therapeutics0.8119 of 5 stars$23.01flat$23.000.0%N/A$389.61M$37.34M-2.6353News CoverageCBMGCellular Biomedicine GroupN/AN/AN/AN/A$384.69M$340,000.00-6.98217Analyst ForecastNews CoverageMGTXMeiraGTx4.4545 of 5 stars$5.85-0.5%$22.50+284.6%+15.3%$379.66M$8.12M-4.18300ELANElanco Animal Health4.1919 of 5 stars$12.53+0.2%$17.00+35.7%+45.7%$6.19B$4.49B-4.919,300Upcoming EarningsShort Interest ↓CYTKCytokinetics4.2687 of 5 stars$51.51-1.4%$83.93+62.9%+47.6%$6.15B$3.13M-9.59250Upcoming EarningsInsider SellingShort Interest ↓NUVLNuvalent3.2819 of 5 stars$90.92-1.9%$112.40+23.6%+66.2%$5.89BN/A-32.7140Insider SellingBPMCBlueprint Medicines2.218 of 5 stars$83.40+0.8%$118.22+41.8%+51.4%$5.22B$362.80M-24.39640Earnings ReportAnalyst ForecastAnalyst RevisionNews CoverageKRYSKrystal Biotech4.6421 of 5 stars$176.22-0.4%$196.75+11.7%+47.8%$5.03B$166.23M48.28229Upcoming Earnings Related Companies and Tools Related Companies Fusion Pharmaceuticals Alternatives Prevail Therapeutics Alternatives Harpoon Therapeutics Alternatives Cellular Biomedicine Group Alternatives MeiraGTx Alternatives Elanco Animal Health Alternatives Cytokinetics Alternatives Nuvalent Alternatives Blueprint Medicines Alternatives Krystal Biotech Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:TARS) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredMusk Says ‘Dollar Will Be Worth Nothing…’Elon Musk just issued an urgent warning… It's no secret that Musk is able to move markets with his words…Crypto 101 Media | Sponsored[Just Released] Jovine's Emergency Briefing insidePeople didn't believe Jovine when he predicted the 2008 financial crisis over a year in advance. But some read...Behind the Markets | SponsoredHe made 1,303,329 in 12 months after Biden won…Tim Sykes - the world’s most apolitical Millionaire trader - just sat down for an urgent election interview… ...Timothy Sykes | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tarsus Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tarsus Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
